FDA Approves Etcamah for ESR1-Mutant Breast Cancer, Guardant360 CDx as Companion Diagnostic
GH has more than doubled off its 52-week low of $53.4.
Summary
The FDA granted accelerated approval to Etcamah for advanced breast cancer with ESR1 mutation and authorized Guardant360 CDx as a companion diagnostic. This is a major regulatory win for Guardant Health, expanding its oncology portfolio and validating its liquid biopsy platform. The approval follows the June 2026 FDA clearance of Guardant360 CDx for Boehringer Ingelheim's therapy, reinforcing the company's companion diagnostic strategy. With a market cap around $21 billion, this approval could drive significant revenue growth in the precision oncology segment. Investors should watch for commercial launch details and potential reimbursement decisions.
At the time of this announcement, GH was trading at $156.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21B. The 52-week trading range was $53.40 to $176.58. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.